[{"data":1,"prerenderedAt":188},["ShallowReactive",2],{"drug-apomorphine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":34,"contraindications":68,"warnings":78,"renal":92,"monitoring":93,"interactions":94,"review":95,"examples":98,"atc":105,"iran":107,"usApproval":127,"links":133,"populations":153},"apomorphine",1,{"fa":7,"en":8},"آپومورفین","Apomorphine","nervous-system",{"fa":11,"en":12},"آگونیست دوپامین (تزریقی)","Dopamine agonist (injectable)",[14],{"name":15,"market":16},"Apokyn","US",[18,19,7],"apokyn","آپوکین",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"cart-10","injection","sc","10 mg\u002FmL cartridge (30 mg\u002F3 mL) for pen",{"amount":27,"unit":28,"perVolumeMl":5},10,"mg",[16],[31],{"source":32,"section":33},"fda-apokyn","3",[35],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":49,"durationDays":52,"notes":53},"off","parkinsons",{"fa":39,"en":40},"دوره‌های «off» پارکینسون پیشرفته — هر دوز ۰٫۲ mL (۲ mg) زیرجلدی؛ تیتراسیون تا حداکثر ۰٫۶ mL (۶ mg)","Parkinson \"off\" episodes — each dose 0.2 mL (2 mg) SC; titrate to max 0.6 mL (6 mg)",{"minAge":42},{"value":43,"unit":44},18,"year","fixed",{"perDose":47,"perDoseMax":48,"dosesPerDay":5},2,6,[50],{"source":32,"section":51},"2.3",{"min":5,"max":5},[54],{"text":55,"refs":58},{"fa":56,"en":57},"همیشه دوز را به mL بنویسید. اولین دوز زیر نظر پزشک. شروع ۰٫۱ تا ۰٫۲ mL. برای یک دوره off دوز دوم نه؛ فاصله دست‌کم ۲ ساعت. ۳ روز پیش از شروع تری‌متوبنزامید ۳۰۰ mg سه بار. وقفه بیش از یک هفته: از ۰٫۲ mL دوباره. نارسایی خفیف\u002Fمتوسط کلیه: شروع ۰٫۱ mL.","Always express the dose in mL. First dose under medical supervision. Start 0.1–0.2 mL. No second dose for the same off episode; at least 2 h apart. Trimethobenzamide 300 mg three times daily from 3 days before. Interruption >1 week: restart at 0.2 mL. Mild\u002Fmoderate renal impairment: start 0.1 mL.",[59,61,62,64,66],{"source":32,"section":60},"2.1",{"source":32,"section":51},{"source":32,"section":63},"2.5",{"source":32,"section":65},"2.2",{"source":32,"section":67},"2.4",[69],{"id":70,"severity":71,"text":72,"refs":75},"ci","block",{"fa":73,"en":74},"آنتاگونیست‌های 5HT3 (اندانسترون، گرانیسترون، دولاسترون، پالونوسترون، آلوسترون) — افت فشار شدید و کاهش هوشیاری؛ حساسیت به آپومورفین یا سولفیت.","5HT3 antagonists (ondansetron, granisetron, dolasetron, palonosetron, alosetron) — profound hypotension and loss of consciousness; hypersensitivity to apomorphine or sulfite.",[76],{"source":32,"section":77},"4",[79,86],{"text":80,"refs":83},{"fa":81,"en":82},"به خواب رفتن ناگهانی حین فعالیت روزانه؛ توهم؛ افت فشار و سنکوپ؛ رفتار تکانشی و وسواسی (قمار، خرید)؛ دیسکینزی؛ تب و گیجی با قطع ناگهانی.","Falling asleep during daily activities; hallucinations; hypotension and syncope; impulse-control\u002Fcompulsive behaviours (gambling, shopping); dyskinesia; hyperpyrexia and confusion on abrupt withdrawal.",[84],{"source":32,"section":85},"5",{"text":87,"refs":90},{"fa":88,"en":89},"تزریق وریدی نه (ترومبوز)؛ تهوع و استفراغ؛ کم‌خونی همولیتیک؛ رویداد کرونری؛ طولانی شدن QTc؛ پریاپیسم.","Never IV (thrombosis); nausea and vomiting; haemolytic anaemia; coronary events; QTc prolongation; priapism.",[91],{"source":32,"section":85},[],[],[],{"status":96,"reviewer":97,"date":97},"unverified",null,[99],{"regimen":36,"formulation":22,"input":100,"expect":103},{"ageYears":101,"weightKg":102},65,70,{"perDose":47,"mlPerDose":104,"upperPerDose":48},0.2,[106],"N04BC07",{"status":108,"forms":109,"refs":122},"registered",[110,114,118],{"code":111,"en":112,"fa":113},"00101","APOMORPHINE HCL 10MG\u002FML AMP","آمپول آپومورفین هیدروکلراید ۱۰ میلی‌گرم \u002F میلی‌لیتر",{"code":115,"en":116,"fa":117},"11404","APOMORPHINE HCL 500MG TAB","قرص آپومورفین هیدروکلراید ۵۰۰ میلی‌گرم",{"code":119,"en":120,"fa":121},"51973","APOMORPHINE HCL 20MG\u002FML AMP","آمپول آپومورفین هیدروکلراید ۲۰ میلی‌گرم \u002F میلی‌لیتر",[123],{"source":124,"section":125,"url":126},"darooyab-generic","G-2482\u002FApomorphine","https:\u002F\u002Fwww.darooyab.ir\u002FG-2482\u002FApomorphine",{"kind":128,"refs":129,"id":132},"NDA",[130],{"source":32,"section":131},"SPL approval \u002F marketing category","NDA021264",[134,137,141,145,148,151],{"kind":135,"url":136,"label":132},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021264",{"kind":138,"url":139,"label":140},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=3235535d-9ef9-4657-8b2a-176a807d091c","FDA Apokyn",{"kind":142,"url":143,"label":144},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa604020.html","Apomorphine Injection",{"kind":142,"url":146,"label":147},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa620044.html","Apomorphine Sublingual",{"kind":149,"url":150,"label":106},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N04BC07",{"kind":152,"url":126,"label":8},"darooyab",{"pregnancy":154,"lactation":163,"pediatric":171,"geriatric":180},{"level":155,"text":156,"quote":159,"refs":160},"caution",{"fa":157,"en":158},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with use of APOKYN in pregnant women.",[161],{"source":32,"section":162},"8.1",{"level":155,"text":164,"quote":167,"refs":168},{"fa":165,"en":166},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of apomorphine in human milk, the effects of apomorphine on the breastfed infant, or the effects of apomorphine on milk production.",[169],{"source":32,"section":170},"8.2",{"level":172,"text":173,"quote":176,"refs":177},"not-established",{"fa":174,"en":175},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[178],{"source":32,"section":179},"8.4",{"level":155,"text":181,"quote":184,"refs":185},{"fa":182,"en":183},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In the APOKYN clinical development program, there were 239 patients less than age 65 treated with APOKYN and 311 patients who were age 65 or older.",[186],{"source":32,"section":187},"8.5",1792191526302]